References
- Dotis J, Prasad P, Zaoutis T, et al. Epidemiology, risk factors and outcome of C. parapsilosis bloodstream infection in children. Pediatr Infect Dis J 2012;31:557-60
- Benjamin DK Jr, Stoll BJ, Gantz MG, et al. Neonatal candidiasis: epidemiology, risk factors, and clinical judgement. Pediatrics 2010;126:c865-73
- Downey LC, Smith PB, Benjamin DK Jr., et al. Recent advances in the detection of neonatal candidiasis. Curr Fungal Infect Rep 2010;4:17-22
- Zaoutis TE, Argon J, Chu J, et al. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis 2005;41:1232-9
- Neu N, Malik M, Lunding A, et al. Epidemiology of candidemia at a children’s hospital, 2002–2006. Pediatr Infect Dis 2009;28:806-9
- Kullberg BJ, Arendrup MC. Invasive candidiasis. NEJM 2015;373:1445-56
- Pappas PH, Kauffman CA, Andes DR, et al. Clinical practice guidelines for the management of candidiasis: 2016 updated by the Infectious Diseases Society of America. Clin Infect Dis 2016;62:409-17
- Medicode (Firm). ICD-9-CM: International Classification of Diseases, 9th Revision, Clinical Modification. Salt Lake City, Utah: Medicode, 1996
- Healthcare Cost and Utilization Project ? HCUP. A Federal-State-Industry Partnership in Health Data. Sponsored by the Agency for Healthcare Research and Quality. CLINICAL CLASSIFICATIONS SOFTWARE (CCS) 2015. Available at: https://www.hcup-us.ahrq.gov/toolssoftware/ccs/CCSUsersGuide.pdf. Accessed August 14, 2017.
- Chan S, Baley ED, Hossain J, et al. Candida species bloodstream infections in hospitalized children: a 10-year experience. J Pediatr Child Health 2015;51:857-660
- Pappas PG, Rex JH, Lee J, et al. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis 2003;37:634-43
- Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005;49:3640-5
- Linder N, Klinger G, Shalit I, et al. Treatment of candidaemia in premature infants: comparison of three amphotericin B preparations. J Antimicrob Chemother 2003;52:663-7
- Pammi M, Holland L, Butler G, et al. Candida parapsilosis is a significant neonatal pathogen: a systematic review and meta-analysis. Pediatr Infect Dis J 2013;32:e206-16
- Arnold HM, Micek ST, Shorr AF, et al. Hospital resource utilization and costs of inappropriate treatment of candidemia. Pharmacotherapy 2010;30:361-8
- Garey KW, Turpin RS, Bearden DT, et al. Economic analyses of inadequate fluconazole therapy in non-neutropenic patients with candidaemia: a multi-institutional study. Int J Antimicrob Agents 2007;29:557-62
- Garey KW, Rege M, Pai MP, et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 2006;43:25-31
- Smith PB, Morgan J, Benjamin JD, et al. Excess costs of hospital care associated with neonatal candidemia. Pediatr Infect Dis J 2007;26:197-200